Hansoh Pharmaceutical Group Company Limited (3692.HK) News
Track canonical SquawkNews coverage tagged to 3692.HK, Hansoh Pharmaceutical Group Company Limited. This hub brings together deduplicated headlines about hong kong stock exchange, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 2 indexed stories across 1 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
Hansoh Pharma drug meets trial endpoints, shares jump
Shares of Hansoh Pharmaceutical Group rose 4.3% to HK$35.76, their highest level since September 9, after the company said its phase III clinical trial of HS-10374 in treatment of moderate-to-severe plaque psoriasis met
EQUITY | Sep 21, 2026, 03:42 AM UTC
M
Hansoh Pharma psoriasis drug meets Phase 3 trial endpoints
Hansoh Pharma reported positive results from a pivotal Phase 3 trial for its psoriasis drug HS-10374 in adults with moderate-to-severe plaque psoriasis. The study met its primary endpoints, showing clear clinical improve
EQUITY | Sep 21, 2026, 12:27 AM UTC